• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

更正：斯盖尔扎等人。isatuximab、卡非佐米和地塞米松（IsaKd）在自体干细胞移植和来那度胺维持治疗后首次复发的多发性骨髓瘤患者中的疗效和安全性：多中心、真实世界AENEID研究结果。2025年，，595。

Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. 2025, , 595.

作者信息

Sgherza Nicola, Battisti Olga, Curci Paola, Conticello Concetta, Palmieri Salvatore, Derudas Daniele, Germano Candida, Martino Enrica Antonia, Mele Giuseppe, Della Pepa Roberta, Fazio Francesca, Mele Anna, Rossini Bernardo, Palazzo Giulia, Roccotelli Daniela, Rasola Simona, Petrucci Maria Teresa, Pastore Domenico, Tarantini Giuseppe, Pane Fabrizio, Gentile Massimo, Raimondo Francesco Di, Resta Emanuela, Musto Pellegrino

机构信息

Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, 70124 Bari, Italy.

Division of Hematology and Stem Cell Transplantation, Policlinico "G. Rodolico-San Marco", 95123 Catania, Italy.

出版信息

Pharmaceuticals (Basel). 2025 Jun 9;18(6):858. doi: 10.3390/ph18060858.

DOI:10.3390/ph18060858
PMID:40573328
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12196246/
Abstract

In the original publication [...].

摘要

在原始出版物中 [...]。

相似文献

1
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. 2025, , 595.更正：斯盖尔扎等人。isatuximab、卡非佐米和地塞米松（IsaKd）在自体干细胞移植和来那度胺维持治疗后首次复发的多发性骨髓瘤患者中的疗效和安全性：多中心、真实世界AENEID研究结果。2025年，，595。
Pharmaceuticals (Basel). 2025 Jun 9;18(6):858. doi: 10.3390/ph18060858.
2
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study.isatuximab、卡非佐米和地塞米松（IsaKd）用于自体干细胞移植和来那度胺维持治疗后首次复发的多发性骨髓瘤患者的疗效和安全性：多中心、真实世界AENEID研究结果
Pharmaceuticals (Basel). 2025 Apr 19;18(4):595. doi: 10.3390/ph18040595.
3
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.卡非佐米-来那度胺-地塞米松对比来那度胺-地塞米松治疗不适合自体干细胞移植的新诊断骨髓瘤患者（EMN20）：一项随机、开放标签、多中心3期试验
Lancet Haematol. 2025 Aug;12(8):e621-e634. doi: 10.1016/S2352-3026(25)00162-0.
4
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.西达基奥仑赛与标准治疗方案用于既往治疗过的复发或难治性多发性骨髓瘤患者的疗效比较：一项匹配调整间接比较
Adv Ther. 2025 May 12. doi: 10.1007/s12325-025-03205-8.
5
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.isatuximab、硼替佐米、来那度胺与小剂量地塞米松用于不适宜移植的多发性骨髓瘤患者（REST）：一项多中心、单臂、2期试验
Lancet Haematol. 2025 Feb;12(2):e120-e127. doi: 10.1016/S2352-3026(24)00347-8.
6
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial.伊沙妥昔单抗、卡非佐米、来那度胺和地塞米松用于新诊断骨髓瘤的诱导治疗：MIDAS试验分析
Blood. 2025 Jan 22. doi: 10.1182/blood.2024026230.
7
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.多发性骨髓瘤患者挽救性自体干细胞移植后使用卡非佐米和地塞米松维持治疗的健康相关生活质量及质量调整无进展生存期：北欧骨髓瘤研究组的一项随机2期试验
J Patient Rep Outcomes. 2024 Feb 5;8(1):15. doi: 10.1186/s41687-024-00691-2.
8
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.伊沙佐米、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3.
9
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.超高危多发性骨髓瘤患者自体干细胞移植的结果。
Transplant Cell Ther. 2023 Dec;29(12):757-762. doi: 10.1016/j.jtct.2023.08.031. Epub 2023 Sep 4.
10
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.卡非佐米、来那度胺和地塞米松或来那度胺单药作为自体造血干细胞移植后多发性骨髓瘤患者的维持治疗（ATLAS）：一项随机、开放标签、3 期临床试验的中期分析。
Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12.

本文引用的文献

1
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study.isatuximab、卡非佐米和地塞米松（IsaKd）用于自体干细胞移植和来那度胺维持治疗后首次复发的多发性骨髓瘤患者的疗效和安全性：多中心、真实世界AENEID研究结果
Pharmaceuticals (Basel). 2025 Apr 19;18(4):595. doi: 10.3390/ph18040595.